Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis

https://doi.org/10.1200/JCO.2011.38.5724

2.

Kumar

S

,

Dispenzieri

A

,

Lacy

MQ

,

Hayman

SR

,

Buadi

FK

,

Colby

C

, et al.

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements

.

J Clin Oncol

.

2012

Mar

;

30

(

9

):

989

–

95

.

[PubMed]

0732-183X

https://doi.org/10.1182/blood-2016-01-629790

3.

Palladini

G

,

Merlini

G

.

What is new in diagnosis and management of light chain amyloidosis?

Blood

.

2016

Jul

;

128

(

2

):

159

–

68

.

[PubMed]

0006-4971

https://doi.org/10.1007/s12016-009-8163-9

4.

Bhat

A

,

Selmi

C

,

Naguwa

SM

,

Cheema

GS

,

Gershwin

ME

.

Currents concepts on the immunopathology of amyloidosis

.

Clin Rev Allergy Immunol

.

2010

Apr

;

38

(

2-3

):

97

–

106

.

[PubMed]

1080-0549

5.

G M

, editor. AL amyloidosis: from molecular mechanisms to targeted therapies. ASH;

2017

; Atlanta, GA.

6.

Kyle

RA

,

Linos

A

,

Beard

CM

,

Linke

RP

,

Gertz

MA

,

O’Fallon

WM

, et al.

Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989

.

Blood

.

1992

Apr

;

79

(

7

):

1817

–

22

.

[PubMed]

0006-4971

https://doi.org/10.1182/bloodadvances.2018016402

7.

Quock

TP

,

Yan

T

,

Chang

E

,

Guthrie

S

,

Broder

MS

.

Epidemiology of AL amyloidosis: a real-world study using US claims data

.

Blood Adv

.

2018

May

;

2

(

10

):

1046

–

53

.

[PubMed]

2473-9529

https://doi.org/10.1111/bjh.13155

8.

Wechalekar

AD

,

Gillmore

JD

,

Bird

J

,

Cavenagh

J

,

Hawkins

S

,

Kazmi

M

, et al.;

BCSH Committee

.

Guidelines on the management of AL amyloidosis

.

Br J Haematol

.

2015

Jan

;

168

(

2

):

186

–

206

.

[PubMed]

0007-1048

https://doi.org/10.1007/s40271-017-0273-5

9.

McCausland

KL

,

White

MK

,

Guthrie

SD

,

Quock

T

,

Finkel

M

,

Lousada

I

, et al.

Light Chain (AL) Amyloidosis: The Journey to Diagnosis

.

Patient

.

2018

Apr

;

11

(

2

):

207

–

16

.

[PubMed]

1178-1653

10.

Sher

T

,

Hayman

SR

,

Gertz

MA

.

Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy

.

[Erratum appears in Clin Adv Hematol Oncol. 2012 Nov;10(11):766]

.

Clin Adv Hematol Oncol

.

2012

Oct

;

10

(

10

):

644

–

51

.

[PubMed]

1543-0790

11.

Kyle

RA

,

Gertz

MA

.

Primary systemic amyloidosis: clinical and laboratory features in 474 cases

.

Semin Hematol

.

1995

Jan

;

32

(

1

):

45

–

59

.

[PubMed]

0037-1963

https://doi.org/10.1093/qjmed/91.2.141

12.

Dubrey

SW

,

Cha

K

,

Anderson

J

,

Chamarthi

B

,

Reisinger

J

,

Skinner

M

, et al.

The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement

.

QJM

.

1998

Feb

;

91

(

2

):

141

–

57

.

[PubMed]

1460-2725

https://doi.org/10.1111/j.1468-1331.2010.03215.x

13.

Matsuda

M

,

Gono

T

,

Morita

H

,

Katoh

N

,

Kodaira

M

,

Ikeda

S

.

Peripheral nerve involvement in primary systemic AL amyloidosis: a clinical and electrophysiological study

.

Eur J Neurol

.

2011

Apr

;

18

(

4

):

604

–

10

.

[PubMed]

1351-5101

https://doi.org/10.2169/internalmedicine.9206-17

14.

Shimazaki

C

,

Hata

H

,

Iida

S

,

Ueda

M

,

Katoh

N

,

Sekijima

Y

, et al.

Nationwide Survey of 741 Patients with Systemic Amyloid Light-chain Amyloidosis in Japan

.

Intern Med

.

2018

Jan

;

57

(

2

):

181

–

7

.

[PubMed]

0918-2918

https://doi.org/10.1161/01.CIR.0000068314.02595.B2

15.

Palladini

G

,

Campana

C

,

Klersy

C

,

Balduini

A

,

Vadacca

G

,

Perfetti

V

, et al.

Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis

.

Circulation

.

2003

May

;

107

(

19

):

2440

–

5

.

[PubMed]

0009-7322

https://doi.org/10.1016/j.amjcard.2004.10.028

16.

Murtagh

B

,

Hammill

SC

,

Gertz

MA

,

Kyle

RA

,

Tajik

AJ

,

Grogan

M

.

Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement

.

Am J Cardiol

.

2005

Feb

;

95

(

4

):

535

–

7

.

[PubMed]

0002-9149

https://doi.org/10.1093/ehjci/jew101

17.

Bhatti

S

,

Watts

E

,

Syed

F

,

Vallurupalli

S

,

Pandey

T

,

Jambekar

K

, et al.

Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis

.

Eur Heart J Cardiovasc Imaging

.

2016

Sep

;

17

(

9

):

970

–

7

.

[PubMed]

2047-2404

https://doi.org/10.1016/j.jacc.2007.10.049

18.

Vogelsberg

H

,

Mahrholdt

H

,

Deluigi

CC

,

Yilmaz

A

,

Kispert

EM

,

Greulich

S

, et al.

Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy

.

J Am Coll Cardiol

.

2008

Mar

;

51

(

10

):

1022

–

30

.

[PubMed]

0735-1097

19.

Papantoniou

V

,

Valsamaki

P

,

Kastritis

S

,

Tsiouris

S

,

Delichas

Z

,

Papantoniou

Y

, et al.

Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy

.

Hell J Nucl Med

.

2015

Sep-Dec

;

18

Suppl 1

:

42

–

50

.

[PubMed]

1790-5427

https://doi.org/10.1007/s12350-016-0478-3

20.

Harb

SC

,

Haq

M

,

Flood

K

,

Guerrieri

A

,

Passerell

W

,

Jaber

WA

, et al.

National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy

.

J Nucl Cardiol

.

2017

Jun

;

24

(

3

):

1094

–

7

.

[PubMed]

1071-3581

https://doi.org/10.1055/s-0043-120924

21.

Franck

C

,

Venerito

M

,

Weigt

J

,

Roessner

A

,

Malfertheiner

P

.

Recurrent diffuse gastric bleeding as a leading symptom of gastrointestinal AL amyloidosis

.

Z Gastroenterol

.

2017

Dec

;

55

(

12

):

1318

–

22

.

[PubMed]

0044-2771

https://doi.org/10.1159/000489297

22.

Hoscheit

M

,

Kamal

A

,

Cline

M

.

Gastroparesis in a Patient with Gastric AL Amyloidosis

.

Case Rep Gastroenterol

.

2018

Jun

;

12

(

2

):

317

–

21

.

[PubMed]

1662-0631

https://doi.org/10.1046/j.1365-2141.2000.02183.x

23.

Mumford

AD

,

O’Donnell

J

,

Gillmore

JD

,

Manning

RA

,

Hawkins

PN

,

Laffan

M

.

Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis

.

Br J Haematol

.

2000

Aug

;

110

(

2

):

454

–

60

.

[PubMed]

0007-1048

https://doi.org/10.1001/jama.1983.03330340064034

24.

Yood

RA

,

Skinner

M

,

Rubinow

A

,

Talarico

L

,

Cohen

AS

.

Bleeding manifestations in 100 patients with amyloidosis

.

JAMA

.

1983

Mar

;

249

(

10

):

1322

–

4

.

[PubMed]

0098-7484

https://doi.org/10.1007/s00277-009-0857-9

25.

Petruzziello

F

,

Zeppa

P

,

Catalano

L

,

Cozzolino

I

,

Gargiulo

G

,

Musto

P

, et al.

Amyloid in bone marrow smears of patients affected by multiple myeloma

.

Ann Hematol

.

2010

May

;

89

(

5

):

469

–

74

.

[PubMed]

0939-5555

https://doi.org/10.1016/0002-9343(87)90439-6

26.

Duston

MA

,

Skinner

M

,

Shirahama

T

,

Cohen

AS

.

Diagnosis of amyloidosis by abdominal fat aspiration. Analysis of four years’ experience

.

Am J Med

.

1987

Mar

;

82

(

3

):

412

–

4

.

[PubMed]

0002-9343

https://doi.org/10.1016/j.humpath.2017.11.001

27.

Garcia

Y

,

Collins

AB

,

Stone

JR

.

Abdominal fat pad excisional biopsy for the diagnosis and typing of systemic amyloidosis

.

Hum Pathol

.

2018

Feb

;

72

:

71

–

9

.

[PubMed]

0046-8177

https://doi.org/10.1182/blood-2014-11-609883

28.

Fernández de Larrea

C

,

Verga

L

,

Morbini

P

,

Klersy

C

,

Lavatelli

F

,

Foli

A

, et al.

A practical approach to the diagnosis of systemic amyloidoses

.

Blood

.

2015

Apr

;

125

(

14

):

2239

–

44

.

[PubMed]

0006-4971

https://doi.org/10.1007/s00277-015-2549-y

29.

Suzuki

T

,

Kusumoto

S

,

Yamashita

T

,

Masuda

A

,

Kinoshita

S

,

Yoshida

T

, et al.

Labial salivary gland biopsy for diagnosing immunoglobulin light chain amyloidosis: a retrospective analysis

.

Ann Hematol

.

2016

Jan

;

95

(

2

):

279

–

85

.

[PubMed]

0939-5555

https://doi.org/10.1182/blood-2009-07-230722

30.

Vrana

JA

,

Gamez

JD

,

Madden

BJ

,

Theis

JD

,

Bergen

HR

3rd,

Dogan

A

.

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

.

Blood

.

2009

Dec

;

114

(

24

):

4957

–

9

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2011-06-358507

31.

Schönland

SO

,

Hegenbart

U

,

Bochtler

T

,

Mangatter

A

,

Hansberg

M

,

Ho

AD

, et al.

Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients

.

Blood

.

2012

Jan

;

119

(

2

):

488

–

93

.

[PubMed]

0006-4971

https://doi.org/10.1056/NEJM199008233230803

32.

Hawkins

PN

,

Lavender

JP

,

Pepys

MB

.

Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component

.

N Engl J Med

.

1990

Aug

;

323

(

8

):

508

–

13

.

[PubMed]

0028-4793

https://doi.org/10.1016/S1470-2045(14)70442-5

33.

Rajkumar

SV

,

Dimopoulos

MA

,

Palumbo

A

,

Blade

J

,

Merlini

G

,

Mateos

MV

, et al.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

.

Lancet Oncol

.

2014

Nov

;

15

(

12

):

e538

–

48

.

[PubMed]

1470-2045

https://doi.org/10.1080/13506120600876773

34.

Biewend

ML

,

Menke

DM

,

Calamia

KT

.

The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature

.

Amyloid

.

2006

Sep

;

13

(

3

):

135

–

42

.

[PubMed]

1350-6129

https://doi.org/10.1007/s40257-017-0278-9

35.

Weidner

T

,

Illing

T

,

Elsner

P

.

Primary Localized Cutaneous Amyloidosis: A Systematic Treatment Review

.

Am J Clin Dermatol

.

2017

Oct

;

18

(

5

):

629

–

42

.

[PubMed]

1175-0561

https://doi.org/10.1016/j.jvoice.2008.07.006

36.

Gallivan

GJ

,

Gallivan

HK

.

Laryngeal amyloidosis causing hoarseness and airway obstruction.

Journal of voice : official journal of the Voice Foundation.

2010

;24(2):235-9.

https://doi.org/10.1080/13506120500351174

37.

Paccalin

M

,

Hachulla

E

,

Cazalet

C

,

Tricot

L

,

Carreiro

M

,

Rubi

M

, et al.

Localized amyloidosis: a survey of 35 French cases

.

Amyloid

.

2005

Dec

;

12

(

4

):

239

–

45

.

[PubMed]

1350-6129

https://doi.org/10.2169/internalmedicine.52.0944

38.

Ogasawara

N

,

Kitagawa

W

,

Obayashi

K

,

Itoh

Y

,

Noda

H

,

Funaki

Y

, et al.

Solitary amyloidosis of the sigmoid colon featuring submucosal tumor caused hematochezia

.

Intern Med

.

2013

;

52

(

22

):

2523

–

7

.

[PubMed]

0918-2918

https://doi.org/10.1016/j.mayocp.2017.02.016

39.

Kourelis

TV

,

Kyle

RA

,

Dingli

D

,

Buadi

FK

,

Kumar

SK

,

Gertz

MA

, et al.

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience

.

Mayo Clin Proc

.

2017

Jun

;

92

(

6

):

908

–

17

.

[PubMed]

0025-6196

https://doi.org/10.1016/j.juro.2010.03.069

40.

Javed

A

,

Canales

BK

,

Maclennan

GT

.

Bladder amyloidosis

.

J Urol

.

2010

Jun

;

183

(

6

):

2388

–

9

.

[PubMed]

0022-5347

https://doi.org/10.1016/S2352-3026(15)00068-X

41.

Mahmood

S

,

Bridoux

F

,

Venner

CP

,

Sachchithanantham

S

,

Gilbertson

JA

,

Rowczenio

D

, et al.

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study

.

Lancet Haematol

.

2015

Jun

;

2

(

6

):

e241

–

50

.

[PubMed]

2352-3026

https://doi.org/10.1182/blood-2007-11-122101

42.

Bochtler

T

,

Hegenbart

U

,

Cremer

FW

,

Heiss

C

,

Benner

A

,

Hose

D

, et al.

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability

.

Blood

.

2008

May

;

111

(

9

):

4700

–

5

.

[PubMed]

0006-4971

https://doi.org/10.1038/leu.2016.369

43.

Muchtar

E

,

Dispenzieri

A

,

Kumar

SK

,

Ketterling

RP

,

Dingli

D

,

Lacy

MQ

, et al.

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

.

Leukemia

.

2017

Jul

;

31

(

7

):

1562

–

9

.

[PubMed]

0887-6924

https://doi.org/10.1200/JCO.2014.57.4947

44.

Bochtler

T

,

Hegenbart

U

,

Kunz

C

,

Granzow

M

,

Benner

A

,

Seckinger

A

, et al.

Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens

.

J Clin Oncol

.

2015

Apr

;

33

(

12

):

1371

–

8

.

[PubMed]

0732-183X

https://doi.org/10.1182/blood-2015-10-676361

45.

Bochtler

T

,

Hegenbart

U

,

Kunz

C

,

Benner

A

,

Kimmich

C

,

Seckinger

A

, et al.

Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study

.

Blood

.

2016

Jul

;

128

(

4

):

594

–

602

.

[PubMed]

0006-4971

https://doi.org/10.1016/j.clml.2018.07.292

46.

Wong

SW

,

Hegenbart

U

,

Palladini

G

,

Shah

GL

,

Landau

HJ

,

Warner

M

, et al.

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p

.

Clin Lymphoma Myeloma Leuk

.

2018

Nov

;

18

(

11

):

e493

–

9

.

[PubMed]

2152-2650

https://doi.org/10.1182/blood-2004-01-0390

47.

Dispenzieri

A

,

Gertz

MA

,

Kyle

RA

,

Lacy

MQ

,

Burritt

MF

,

Therneau

TM

, et al.

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

.

Blood

.

2004

Sep

;

104

(

6

):

1881

–

7

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2010-05-286567

48.

Palladini

G

,

Barassi

A

,

Klersy

C

,

Pacciolla

R

,

Milani

P

,

Sarais

G

, et al.

The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis

.

Blood

.

2010

Nov

;

116

(

18

):

3426

–

30

.

[PubMed]

0006-4971

https://doi.org/10.1080/10428190701684518

49.

Gertz

M

,

Lacy

M

,

Dispenzieri

A

,

Hayman

S

,

Kumar

S

,

Buadi

F

, et al.

Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis

.

Leuk Lymphoma

.

2008

Jan

;

49

(

1

):

36

–

41

.

[PubMed]

1042-8194

http://msmart.org/amyloid.pdf [

50.

51.

Kourelis

TV

,

Kumar

SK

,

Gertz

MA

,

Lacy

MQ

,

Buadi

FK

,

Hayman

SR

, et al.

Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis

.

J Clin Oncol

.

2013

Dec

;

31

(

34

):

4319

–

24

.

https://doi.org/10.1200/JCO.2013.50.8499

[PubMed]

0732-183X

https://doi.org/10.1182/blood-2010-06-290668

52.

Kumar

S

,

Dispenzieri

A

,

Katzmann

JA

,

Larson

DR

,

Colby

CL

,

Lacy

MQ

, et al.

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features

.

Blood

.

2010

Dec

;

116

(

24

):

5126

–

9

.

[PubMed]

0006-4971

https://doi.org/10.1111/bjh.14908

53.

Sachchithanantham

S

,

Berlanga

O

,

Alvi

A

,

Mahmood

SA

,

Lachmann

HJ

,

Gillmore

JD

, et al.

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis

.

Br J Haematol

.

2017

Nov

;

179

(

4

):

575

–

85

.

[PubMed]

0007-1048

https://doi.org/10.1038/leu.2016.140

54.

Muchtar

E

,

Dispenzieri

A

,

Kumar

SK

,

Buadi

FK

,

Lacy

MQ

,

Zeldenrust

S

, et al.

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

.

Leukemia

.

2017

Jan

;

31

(

1

):

92

–

9

.

[PubMed]

0887-6924

https://doi.org/10.1080/13506129.2017.1360272

55.

Rubinstein

S

,

Cornell

RF

,

Du

L

,

Concepcion

B

,

Goodman

S

,

Harrell

S

, et al.

Novel pathologic scoring tools predict end-stage kidney disease in light chain (AL) amyloidosis

.

Amyloid

.

2017

Sep

;

24

(

3

):

205

–

11

.

[PubMed]

1350-6129

https://doi.org/10.1038/s41375-018-0060-x

56.

Muchtar

E

,

Dispenzieri

A

,

Leung

N

,

Lacy

MQ

,

Buadi

FK

,

Dingli

D

, et al.

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria

.

Leukemia

.

2018

Oct

;

32

(

10

):

2240

–

9

.

[PubMed]

0887-6924

https://doi.org/10.1161/01.CIR.63.6.1285

57.

Rubinow

A

,

Skinner

M

,

Cohen

AS

.

Digoxin sensitivity in amyloid cardiomyopathy

.

Circulation

.

1981

Jun

;

63

(

6

):

1285

–

8

.

[PubMed]

0009-7322

https://doi.org/10.1111/jce.12123

58.

Lin

G

,

Dispenzieri

A

,

Kyle

R

,

Grogan

M

,

Brady

PA

.

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

.

J Cardiovasc Electrophysiol

.

2013

Jul

;

24

(

7

):

793

–

8

.

[PubMed]

1045-3873

https://doi.org/10.1093/eurheartj/ehu506

59.

Sayed

RH

,

Rogers

D

,

Khan

F

,

Wechalekar

AD

,

Lachmann

HJ

,

Fontana

M

, et al.

A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis

.

Eur Heart J

.

2015

May

;

36

(

18

):

1098

–

105

.

[PubMed]

0195-668X

https://doi.org/10.7205/MILMED-D-16-00122

60.

Scully

MS

,

Wessman

DE

,

McKee

JM

,

Francisco

GM

,

Nayak

KR

,

Kobashigawa

JA

.

Total Artificial Heart Implantation as a Bridge to Heart Transplantation in an Active Duty Service Member With Amyloid Cardiomyopathy

.

Mil Med

.

2017

Mar

;

182

(

3

):

e1858

–

60

.

[PubMed]

0026-4075

https://doi.org/10.1111/j.1600-6143.2010.03227.x

61.

Sattianayagam

PT

,

Gibbs

SD

,

Pinney

JH

,

Wechalekar

AD

,

Lachmann

HJ

,

Whelan

CJ

, et al.

Solid organ transplantation in AL amyloidosis

.

Am J Transplant

.

2010

Sep

;

10

(

9

):

2124

–

31

.

[PubMed]

1600-6135

https://doi.org/10.1182/blood-2005-08-3253

62.

Gillmore

JD

,

Goodman

HJ

,

Lachmann

HJ

,

Offer

M

,

Wechalekar

AD

,

Joshi

J

, et al.

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

.

Blood

.

2006

Feb

;

107

(

3

):

1227

–

9

.

[PubMed]

0006-4971

63.

Lacy

MQ

,

Dispenzieri

A

,

Hayman

SR

,

Kumar

S

,

Kyle

RA

,

Rajkumar

SV

, et al. Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

2008

;27(8):823-9.

64.

Bansal

T

,

Garg

A

,

Snowden

JA

,

McKane

W

.

Defining the role of renal transplantation in the modern management of multiple myeloma and other plasma cell dyscrasias

.

Nephron Clin Pract

.

2012

;

120

(

4

):

c228

–

35

.

[PubMed]

1660-2110

https://doi.org/10.1177/0148607113501328

65.

Caccialanza

R

,

Palladini

G

,

Klersy

C

,

Cereda

E

,

Bonardi

C

,

Cameletti

B

, et al.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment

.

JPEN J Parenter Enteral Nutr

.

2014

Sep

;

38

(

7

):

891

–

4

.

[PubMed]

0148-6071

https://doi.org/10.1016/S0002-9343(97)89487-9

66.

Skinner

M

,

Anderson

J

,

Simms

R

,

Falk

R

,

Wang

M

,

Libbey

C

, et al.

Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only

.

Am J Med

.

1996

Mar

;

100

(

3

):

290

–

8

.

[PubMed]

0002-9343

https://doi.org/10.1182/blood-2007-02-076034

67.

Palladini

G

,

Russo

P

,

Nuvolone

M

,

Lavatelli

F

,

Perfetti

V

,

Obici

L

, et al.

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

.

Blood

.

2007

Jul

;

110

(

2

):

787

–

8

.

[PubMed]

0006-4971

https://doi.org/10.3324/haematol.12982

68.

Gertz

MA

,

Lacy

MQ

,

Lust

JA

,

Greipp

PR

,

Witzig

TE

,

Kyle

RA

.

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

.

Haematologica

.

2008

Sep

;

93

(

9

):

1402

–

6

.

[PubMed]

0390-6078

https://doi.org/10.3324/haematol.2013.095463

69.

Palladini

G

,

Milani

P

,

Foli

A

,

Obici

L

,

Lavatelli

F

,

Nuvolone

M

, et al.

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach

.

Haematologica

.

2014

Apr

;

99

(

4

):

743

–

50

.

[PubMed]

0390-6078

https://doi.org/10.1182/blood-2018-04-845396

70.

Milani

P

,

Schönland

S

,

Merlini

G

,

Kimmich

C

,

Foli

A

,

Dittrich

T

, et al.

Treatment of AL amyloidosis with bendamustine: a study of 122 patients

.

Blood

.

2018

Nov

;

132

(

18

):

1988

–

91

.

[PubMed]

0006-4971

https://doi.org/10.1200/JCO.2015.62.4015

71.

D’Souza

A

,

Dispenzieri

A

,

Wirk

B

,

Zhang

MJ

,

Huang

J

,

Gertz

MA

, et al.

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

.

J Clin Oncol

.

2015

Nov

;

33

(

32

):

3741

–

9

.

[PubMed]

0732-183X

https://doi.org/10.1038/bmt.2012.170

72.

Gertz

MA

,

Lacy

MQ

,

Dispenzieri

A

,

Kumar

SK

,

Dingli

D

,

Leung

N

, et al.

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis

.

Bone Marrow Transplant

.

2013

Apr

;

48

(

4

):

557

–

61

.

[PubMed]

0268-3369

https://doi.org/10.1200/JCO.2010.31.4161

73.

Bashir

Q

,

Langford

LA

,

Parmar

S

,

Champlin

RE

,

Qazilbash

MH

.

Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection

.

J Clin Oncol

.

2011

Feb

;

29

(

4

):

e79

–

80

.

[PubMed]

0732-183X

https://doi.org/10.1007/s40262-018-0702-1

74.

Gupta

N

,

Hanley

MJ

,

Xia

C

,

Labotka

R

,

Harvey

RD

,

Venkatakrishnan

K

.

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

.

Clin Pharmacokinet

.

2018

Aug

.

[PubMed]

0312-5963

https://doi.org/10.1016/j.clml.2014.02.003

75.

Scott

EC

,

Heitner

SB

,

Dibb

W

,

Meyers

G

,

Smith

SD

,

Abar

F

, et al.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study

.

Clin Lymphoma Myeloma Leuk

.

2014

Oct

;

14

(

5

):

424

–

430.e1

.

[PubMed]

2152-2650

https://doi.org/10.1016/j.bbmt.2018.07.010

76.

Afrough

A

,

Saliba

RM

,

Hamdi

A

,

Honhar

M

,

Varma

A

,

Cornelison

AM

, et al.

Impact of Induction Therapy on the Outcome of Immunoglobulin Light Chain Amyloidosis after Autologous Hematopoietic Stem Cell Transplantation

.

Biol Blood Marrow Transplant

.

2018

Nov

;

24

(

11

):

2197

–

203

.

[PubMed]

1083-8791

https://doi.org/10.1056/NEJMoa070484

77.

Jaccard

A

,

Moreau

P

,

Leblond

V

,

Leleu

X

,

Benboubker

L

,

Hermine

O

, et al.;

Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup

.

High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis

.

N Engl J Med

.

2007

Sep

;

357

(

11

):

1083

–

93

.

[PubMed]

0028-4793

https://doi.org/10.1002/cncr.30051

78.

Gertz

MA

,

Lacy

MQ

,

Dispenzieri

A

,

Buadi

FK

,

Dingli

D

,

Hayman

SR

, et al.

Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis

.

Cancer

.

2016

Jul

;

122

(

14

):

2197

–

205

.

[PubMed]

0008-543X

https://doi.org/10.3324/haematol.2014.119198

79.

Hazenberg

BP

,

Croockewit

A

,

van der Holt

B

,

Zweegman

S

,

Bos

GM

,

Delforge

M

, et al.;

Dutch-Belgian Cooperative Trial Group for Hematology Oncology

.

Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology

.

Haematologica

.

2015

May

;

100

(

5

):

677

–

82

.

[PubMed]

0390-6078

https://doi.org/10.1182/blood-2017-06-788729

80.

Browning

S

,

Quillen

K

,

Sloan

JM

,

Doros

G

,

Sarosiek

S

,

Sanchorawala

V

.

Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation

.

Blood

.

2017

Sep

;

130

(

11

):

1383

–

6

.

[PubMed]

0006-4971

https://doi.org/10.1002/hon.2351

81.

Jelinek

T

,

Kryukova

E

,

Kufova

Z

,

Kryukov

F

,

Hajek

R

.

Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity

.

Hematol Oncol

.

2017

Dec

;

35

(

4

):

408

–

19

.

[PubMed]

0278-0232

https://doi.org/10.3324/haematol.11325

82.

Kastritis

E

,

Anagnostopoulos

A

,

Roussou

M

,

Toumanidis

S

,

Pamboukas

C

,

Migkou

M

, et al.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone

.

Haematologica

.

2007

Oct

;

92

(

10

):

1351

–

8

.

[PubMed]

0390-6078

https://doi.org/10.1038/leu.2014.227

83.

Palladini

G

,

Milani

P

,

Foli

A

,

Vidus Rosin

M

,

Basset

M

,

Lavatelli

F

, et al.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients

.

Leukemia

.

2014

Dec

;

28

(

12

):

2311

–

6

.

[PubMed]

0887-6924

https://doi.org/10.1182/blood-2009-02-203398

84.

Reece

DE

,

Sanchorawala

V

,

Hegenbart

U

,

Merlini

G

,

Palladini

G

,

Fermand

JP

, et al.;

VELCADE CAN2007 Study Group

.

Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study

.

Blood

.

2009

Aug

;

114

(

8

):

1489

–

97

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2011-11-390930

85.

Mikhael

JR

,

Schuster

SR

,

Jimenez-Zepeda

VH

,

Bello

N

,

Spong

J

,

Reeder

CB

, et al.

Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis

.

Blood

.

2012

May

;

119

(

19

):

4391

–

4

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2015-01-620302

86.

Palladini

G

,

Sachchithanantham

S

,

Milani

P

,

Gillmore

J

,

Foli

A

,

Lachmann

H

, et al.

A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis

.

Blood

.

2015

Jul

;

126

(

5

):

612

–

5

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2017-03-771220

87.

Adam

D

. Cohen ECS, Michaela Liedtke, Jonathan L. Kaufman, Heather Landau, David H. Vesole, Christina L. Gomes, Cristina Gasparetto, Suzanne Lentzsch, Michael Rosenzweig, Vaishali Sanchorawala, David D. Smith, Raymond L. Comenzo, and Brian G. M. Durie, editor A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis. ASH;

2014

.

88.

Sanchorawala

V

,

Palladini

G

,

Kukreti

V

,

Zonder

JA

,

Cohen

AD

,

Seldin

DC

, et al.

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

.

Blood

.

2017

Aug

;

130

(

5

):

597

–

605

.

[PubMed]

0006-4971

https://doi.org/10.3816/CLM.2003.n.005

89.

Seldin

DC

,

Choufani

EB

,

Dember

LM

,

Wiesman

JF

,

Berk

JL

,

Falk

RH

, et al.

Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis

.

Clin Lymphoma

.

2003

Mar

;

3

(

4

):

241

–

6

.

[PubMed]

1526-9655

https://doi.org/10.3109/13506120309041743

90.

Dispenzieri

A

,

Lacy

MQ

,

Rajkumar

SV

,

Geyer

SM

,

Witzig

TE

,

Fonseca

R

, et al.

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

.

Amyloid

.

2003

Dec

;

10

(

4

):

257

–

61

.

[PubMed]

1350-6129

https://doi.org/10.1002/ajh.21822

91.

Dispenzieri

A

,

Dingli

D

,

Kumar

SK

,

Rajkumar

SV

,

Lacy

MQ

,

Hayman

S

, et al.

Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs

.

Am J Hematol

.

2010

Oct

;

85

(

10

):

757

–

9

.

[PubMed]

0361-8609

https://doi.org/10.1182/blood-2006-07-032987

92.

Dispenzieri

A

,

Lacy

MQ

,

Zeldenrust

SR

,

Hayman

SR

,

Kumar

SK

,

Geyer

SM

, et al.

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

.

Blood

.

2007

Jan

;

109

(

2

):

465

–

70

.

[PubMed]

0006-4971

https://doi.org/10.3324/haematol.2013.084574

93.

Dinner

S

,

Witteles

W

,

Afghahi

A

,

Witteles

R

,

Arai

S

,

Lafayette

R

, et al.

Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement

.

Haematologica

.

2013

Oct

;

98

(

10

):

1593

–

9

.

[PubMed]

0390-6078

https://doi.org/10.1182/blood-2016-12-756528

94.

Palladini

G

,

Milani

P

,

Foli

A

,

Basset

M

,

Russo

F

,

Perlini

S

, et al.

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis

.

Blood

.

2017

Apr

;

129

(

15

):

2120

–

3

.

[PubMed]

0006-4971

https://doi.org/10.1182/blood-2017-01-763599

95.

Kaufman

GP

,

Schrier

SL

,

Lafayette

RA

,

Arai

S

,

Witteles

RM

,

Liedtke

M

.

Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis

.

Blood

.

2017

Aug

;

130

(

7

):

900

–

2

.

[PubMed]

0006-4971

https://doi.org/10.3324/haematol.2017.183749

96.

Abeykoon

JP

,

Dispenzieri

A

, et al., editors. Daratumumab-based therapies in patients with AL amyloidosis. The XVIth International Symposium on Amyloidosis; March 26-29; Kumamoto, Japan

2018

; Kumamoto, Japan.

97.

Leung

N

,

Thomé

SD

,

Dispenzieri

A

.

Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone

.

Haematologica

.

2018

Mar

;

103

(

3

):

e135

–

7

.

[PubMed]

0390-6078

https://doi.org/10.1002/ajh.20381

98.

Gertz

MA

,

Comenzo

R

,

Falk

RH

,

Fermand

JP

,

Hazenberg

BP

,

Hawkins

PN

, et al.

Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004

.

Am J Hematol

.

2005

Aug

;

79

(

4

):

319

–

28

.

[PubMed]

0361-8609

https://doi.org/10.1200/JCO.2011.37.7614

99.

Palladini

G

,

Dispenzieri

A

,

Gertz

MA

,

Kumar

S

,

Wechalekar

A

,

Hawkins

PN

, et al.

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

.

J Clin Oncol

.

2012

Dec

;

30

(

36

):

4541

–

9

.

[PubMed]

0732-183X